SRF plunges 8% on less-than-expected Q3 results
In an earnings call the company said that it was focusing on accelerating qualifications of various new molecules in both agro and pharmaceutical sectors.

The company had reported a net profit of Rs Rs 79.82 crore in the corresponding quarter of last year. Sales for the quarter grew 5.98 per cent at Rs 891.50 crore, compared with Rs 841.19 crore in the same quarter last year.
In an earnings call the company said that it was focusing on accelerating qualifications of various new molecules in both agro and pharmaceutical sectors.
The company said that it is focused “on increasing pace of R&D efforts, efficient cost structures, enhanced capabilities and value-added products in the portfolio,” the company said.
Besides, the company said that it has increased capex to ensure that it has capacities in place to meet the expected rebound.
The stock fell 7.81 per cent to hit a low of Rs 1,615.15 on BSE.
Download ET Markets APP